(VIANEWS) – CAMBODGE NOM. (CBDG.PA), ABG SUNDAL COLLIER (ABG.OL), VEIDEKKE (VEI.OL) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up to now. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. CAMBODGE NOM. (CBDG.PA)
1565.22% Payout Ratio
Compagnie du Cambodge, together with its subsidiaries, provides transportation and logistics services in France. It operates a railway concession linking Burkina Faso with Ivory Coast. The company was incorporated in 1998 and is headquartered in Puteaux, France. Compagnie du Cambodge is a subsidiary of Plantations Des Terres Rouges S.A.
Earnings Per Share
As for profitability, CAMBODGE NOM. has a trailing twelve months EPS of €20.15.
PE Ratio
CAMBODGE NOM. has a trailing twelve months price to earnings ratio of 325.06. Meaning, the purchaser of the share is investing €325.06 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.17%.
Moving Average
CAMBODGE NOM.’s worth is below its 50-day moving average of €6,608.00 and way higher than its 200-day moving average of €5,818.25.
Yearly Top and Bottom Value
CAMBODGE NOM.’s stock is valued at €6,550.00 at 07:10 EST, under its 52-week high of €6,800.00 and way above its 52-week low of €5,100.00.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 9, 2022, the estimated forward annual dividend rate is 180 and the estimated forward annual dividend yield is 2.77%.
More news about CAMBODGE NOM..
2. ABG SUNDAL COLLIER (ABG.OL)
222.22% Payout Ratio
ABG Sundal Collier Holding ASA, together with its subsidiaries, provides investment banking, stockbroking, and corporate advisory services in Norway, Sweden, Denmark, and internationally. The company offers corporate financing services for corporate clients to raise capital through equity or debt financing. It is also involved in advising companies in relation to mergers, acquisitions, and sales, as well as to various real asset transactions and other advisory services. In addition, the company provides secondary security brokerage and research services. The company was founded in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ABG SUNDAL COLLIER has a trailing twelve months EPS of kr0.37.
PE Ratio
ABG SUNDAL COLLIER has a trailing twelve months price to earnings ratio of 15.81. Meaning, the purchaser of the share is investing kr15.81 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.81%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ABG SUNDAL COLLIER’s EBITDA is 1.76.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 27, 2023, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 8.58%.
More news about ABG SUNDAL COLLIER.
3. VEIDEKKE (VEI.OL)
86.42% Payout Ratio
Veidekke ASA operates as a construction and property development company. It operates through Construction Norway, Infrastructure Norway, Construction Sweden, Infrastructure Sweden, and Denmark/Hoffmann segments. The company operates as a construction contractor; executes civil engineering and renovation projects; and produces asphalt and aggregates, as well as operates in the public road maintenance market. It is also involved in the civil engineering, recycling, and asphalting projects, as well as constructs commercial and residential buildings. Veidekke ASA was founded in 1936 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VEIDEKKE has a trailing twelve months EPS of kr8.1.
PE Ratio
VEIDEKKE has a trailing twelve months price to earnings ratio of 14.07. Meaning, the purchaser of the share is investing kr14.07 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.83%.
More news about VEIDEKKE.
4. SANOFI (SAN.PA)
50.08% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.65.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.32. Meaning, the purchaser of the share is investing €14.32 for every euro of annual earnings.
More news about SANOFI.
5. DIAGEO (DGE.PA)
48.74% Payout Ratio
Diageo plc, together with its subsidiaries, produces, markets, and sells alcoholic beverages. The company offers scotch, whisky, gin, vodka, rum, ready to drink products, raki, liqueur, wine, tequila, Canadian whisky, American whiskey, cachaca, and brandy, as well as beer, including cider and non-alcoholic products. It provides its products primarily under the Johnnie Walker, Guinness, Tanqueray, Baileys, Smirnoff, Captain Morgan, Crown Royal, Don Julio, Ciroc, Buchanan's, Casamigos, J&B, and Ketel One brands. The company operates in North America, Europe, Turkey, Africa, Latin America, the Caribbean, the Asia Pacific, and internationally. The company was incorporated in 1886 and is headquartered in London, the United Kingdom.
Earnings Per Share
As for profitability, DIAGEO has a trailing twelve months EPS of €1.8.
PE Ratio
DIAGEO has a trailing twelve months price to earnings ratio of 22.22. Meaning, the purchaser of the share is investing €22.22 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.1%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.4%, now sitting on 16.92B for the twelve trailing months.
Moving Average
DIAGEO’s worth is under its 50-day moving average of €41.19 and under its 200-day moving average of €42.40.
Yearly Top and Bottom Value
DIAGEO’s stock is valued at €40.00 at 07:10 EST, way under its 52-week high of €48.40 and higher than its 52-week low of €38.60.
More news about DIAGEO.
